The Apitox Program
For Knee Osteoarthritis
A Focused Development Candidate
Apitox is the biopharmaceutical program associated with Nexus Biosys in the supplied APUS corporate presentation.
Apitox is a development program for knee osteoarthritis and it is in Phase III clinical development.
Clinical development status, study initiation, recruitment and regulatory progress should be communicated only through formally approved company announcements and official clinical-trial records.
Development Status
Investigational Product Notice
Apitox is an investigational product in the United States. It has not been approved by the U.S. Food and Drug Administration. Its safety and effectiveness have not been established for commercial use in the United States.